Clinical trials: Conjunctival Diseases
Bacterial Conjunctivitis
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive…
- Trial name
- NCT02432807
- Testing
- Vancomycin 1.1%
- Where
- 16 sites in United States
- Volunteers
- 303 people
- Sponsor
- Kurobe LLC
Conjunctivitis, Allergic
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
The purpose of this study is to evaluate whether bepotastine besilate ophthalmic solution is effective in the treatment of acute allergic conjunctivitis
- Trial name
- NCT00424398
- Testing
- Bepreve, Bepotastine Besilate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
The purpose of this study is to evaluate the effect of the controlled adverse environment (CAE) on Mean Break-Up Area in subjects diagnosed with Dry Eye Syndrome.
- Trial name
- NCT01547936
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- ORA, Inc.
Bacterial Conjunctivitis
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis.
- Trial name
- NCT00972777
- Testing
- Besifloxacin
- Where
- United States
- Volunteers
- 474 people
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Disease
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
- Trial name
- NCT06370039
- Testing
- INV-102, Vehicle
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Invirsa, Inc.
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01732757
- Testing
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Allergan
Acute Infectious Keratoconjunctivitis
Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis
Phase 2, randomized study to assess topically administered eyedrops of INV-102 compared to vehicle during 1-week dosing in participants with Acute Infectious Keratoconjunctivitis (AIK).
- Trial name
- NCT05636228
- Testing
- INV-102, Vehicle
- Where
- 12 sites in United States, Thailand
- Volunteers
- 93 people
- Sponsor
- Invirsa, Inc.
Allergic Conjunctivitis
A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival…
- Trial name
- NCT01275105
- Testing
- Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Eye Therapies, LLC
Keratoconjunctivitis Sicca
A Study Of Tasocitinib In Dry Eye Subjects
This is a phase 2 study to further evaluate the safety and efficacy of tasocitinib (CP-690,550) in the subjects with moderate to severe dry eye disease.
- Trial name
- NCT01226680
- Testing
- Tasocitinib, vehicle for Tasocitinib
- Sponsor
- Pfizer
Allergic Conjunctivitis
Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients
The purpose of this study is to study the safety and efficacy of bepotastine besilate ophthalmic solution in allergic conjunctivitis patients.
- Trial name
- NCT01174823
- Testing
- bepotastine besilate ophthalmic solution
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- Bausch & Lomb Incorporated
Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic
Immunotherapy With Depigmented and Polymerized Allergen Extract of Phleum Pratense
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract of Phleum pratense in the rhinoconjunctivitis and/or asthma of slight or moderate…
- Conditions
- Rhinitis, Allergic, Seasonal, Conjunctivitis, Allergic, Asthma
- Trial name
- NCT00501527
- Testing
- Immunotherapy with modified extract of P. pratense pollen
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Laboratorios Leti, S.L.
Keratoconjunctivitis, Ocular Surface Disease
A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers
In this study, PP-001 eye drops are assessed for safety and tolerability in healthy, adult volunteers. PP-001 is a novel, anti-inflammatory small molecule that inhibits a specific enzyme (Dihydroorotate Dehydrogenase).
- Trial name
- NCT03769454
- Testing
- PP-001
- Where
- Austria
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Panoptes Pharma GmbH
Allergic Conjunctivitis
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season.
- Trial name
- NCT00982163
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- ORA, Inc.
Pterygium
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes…
- Trial name
- NCT05456425
- Testing
- CBT-001, Vehicle
- Where
- 44 sites in United States, Australia and 3 more
- Volunteers
- 660 people
- Sponsor
- Cloudbreak Therapeutics, LLC
Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis
Tyrosine Allergoid Paediatric and Adult Study
The primary objective of this 5-year study is to demonstrate non-inferiority of children compared to adults by exploring long-term effectiveness after treatment with TA Bäume (trees) and TA Gräser (grass) following a perennial…
- Conditions
- Allergic Rhinitis Due to Pollen, Allergic Conjunctivitis, Allergic Asthma
- Trial name
- NCT05186025
- Testing
- MATA trees or MATA grass
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Allergy Therapeutics
Allergic Conjunctivitis
Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients
The objective of this study is to further evaluate the safety of Olopatadine Ophthalmic Solution 0.1% in Japanese children with allergic conjunctivitis.
- Trial name
- NCT01109485
- Testing
- Olopatadine hydrochloride ophthalmic solution 0.1%
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Alcon Research
Dry Eye Disease (DED), Keratoconjunctivitis Sicca
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
- Trial name
- NCT07078955
- Testing
- BRM421 Ophthalmic Solution, 0.03%, Artificial Tear, BRM421 Ophthalmic Solution, 0.06%
- Where
- Taiwan
- Volunteers
- 99 people
- Sponsor
- BRIM Biotechnology Inc.
Bacterial Conjunctivitis
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
The purpose of this study is to evaluate the safety and efficacy of Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle in the treatment of bacterial conjunctivitis in patients one month of age or older.
- Trial name
- NCT00759148
- Testing
- Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%, Moxifloxacin AF Vehicle
- Volunteers
- 1,179 people
- Sponsor
- Alcon Research
Hypersensitivity, Allergic Rhinitis
Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis
The purpose of this 2-year study is to assess the sustained clinical efficacy and safety of 300 IR/day of a sublingual solution of birch pollen allergen extract starting 4 months prior to the birch pollen season and continuing…
- Conditions
- Hypersensitivity, Allergic Rhinitis, Allergic Conjunctivitis, Seasonal Allergy
- Trial name
- NCT01731249
- Testing
- Birch pollen allergen extract
- Where
- 11 sites in Czechia, Denmark and 9 more
- Volunteers
- 574 people
- Sponsor
- Stallergenes Greer
Allergic Conjunctivitis, Allergic Rhinitis
Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections
A safety study conducted on subjects ≥16 years old evaluating the safety of 4 intralymphatic injections of 2 different dose levels of the investigational short and tall ragweed product.
- Trial name
- NCT03038971
- Testing
- Dose Level 1, Dose Level 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Woodmont Pharmaceuticals, Inc.